1.58Open1.58Pre Close0 Volume294 Open Interest10.00Strike Price0.00Turnover109.51%IV5.07%PremiumDec 20, 2024Expiry Date1.13Intrinsic Value100Multiplier4DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type-0.8480Delta0.2413Gamma7.39Leverage Ratio-0.0294Theta-0.0008Rho-6.27Eff Leverage0.0021Vega
Emergent BioSolutions Stock Discussion
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions (NYSE: EBS) has received a $50 million contract option from BARDA for its CYFENDUS® anthrax vaccine. The deliveries are scheduled between now and April 2025. This follows a previous $30 million contract modification for the same vaccine. CYFENDUS®, FDA-approved in July 2023, is a two-dose anthrax vacci...
Just
Emergent BioSolutions Receives $50 Million Contract Option From Barda to Procure Doses of Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted
Emergent BioSolutions Inc - Cyfendus Vaccine Deliveries Expected to Complete by April 2025
$Synopsys (SNPS.US)$ $Futu Holdings Ltd (FUTU.US)$ $IonQ Inc (IONQ.US)$
No comment yet